317 related articles for article (PubMed ID: 24562770)
41. PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Chen L; Jin T; Zhu K; Piao Y; Quan T; Quan C; Lin Z
Oncotarget; 2017 Feb; 8(7):11937-11949. PubMed ID: 28060760
[TBL] [Abstract][Full Text] [Related]
42. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
43. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
[TBL] [Abstract][Full Text] [Related]
44. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
45. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
Feldman ME; Apsel B; Uotila A; Loewith R; Knight ZA; Ruggero D; Shokat KM
PLoS Biol; 2009 Feb; 7(2):e38. PubMed ID: 19209957
[TBL] [Abstract][Full Text] [Related]
46. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
47. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
48. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
50. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
51. Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.
Tandon M; Chen Z; Pratap J
Breast Cancer Res; 2014 Jan; 16(1):R16. PubMed ID: 24479521
[TBL] [Abstract][Full Text] [Related]
52. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
[TBL] [Abstract][Full Text] [Related]
54. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells.
Ondrušová L; Réda J; Záková P; Tuháčková Z
Folia Biol (Praha); 2013; 59(4):162-7. PubMed ID: 24093774
[TBL] [Abstract][Full Text] [Related]
56. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
[TBL] [Abstract][Full Text] [Related]
57. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
[TBL] [Abstract][Full Text] [Related]
60. Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Ramakrishnan V; Kimlinger T; Haug J; Painuly U; Wellik L; Halling T; Rajkumar SV; Kumar S
PLoS One; 2012; 7(11):e50005. PubMed ID: 23185517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]